Accredited Investors Inc. Has $608,000 Stock Holdings in Solventum Co. (NYSE:SOLV)

Accredited Investors Inc. raised its stake in Solventum Co. (NYSE:SOLV) by 14.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,723 shares of the company’s stock after buying an additional 1,079 shares during the period. Accredited Investors Inc.’s holdings in Solventum were worth $608,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SOLV. Davis Selected Advisers acquired a new stake in shares of Solventum during the 2nd quarter valued at $273,070,000. Nuance Investments LLC bought a new position in Solventum in the second quarter valued at about $115,829,000. Newport Trust Company LLC acquired a new stake in shares of Solventum during the second quarter valued at about $98,976,000. Baupost Group LLC MA bought a new stake in shares of Solventum during the second quarter worth about $96,242,000. Finally, Magnetar Financial LLC increased its stake in shares of Solventum by 2,880.8% in the second quarter. Magnetar Financial LLC now owns 1,490,410 shares of the company’s stock valued at $78,813,000 after buying an additional 1,440,410 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SOLV. Stifel Nicolaus started coverage on shares of Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. The Goldman Sachs Group boosted their price objective on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. Piper Sandler increased their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Wolfe Research assumed coverage on Solventum in a report on Thursday, September 26th. They set a “peer perform” rating on the stock. Finally, Wells Fargo & Company decreased their price target on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Solventum presently has a consensus rating of “Hold” and an average price target of $68.00.

Solventum Price Performance

Shares of SOLV stock opened at $67.48 on Friday. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The stock has a 50 day simple moving average of $70.54 and a two-hundred day simple moving average of $62.20.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.